The combination of NDV, EVE, and Beclin-1 constitutes a multifaceted treatment approach designed to address tumor resistance and boost immune responses through increased ICD induction or improved tumor-infiltrating CD8 + T cells [8,14]. This evidence concerns the gene CD8A and neoplasm.